Disclosure statements are available on the authors' profiles:
Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 TrialNeuro-oncology 2022 Apr 14;[EPub Ahead of Print], A Omuro, AA Brandes, AF Carpentier, A Idbaih, DA Reardon, T Cloughesy, A Sumrall, J Baehring, M van den Bent, O Bähr, G Lombardi, P Mulholland, G Tabatabai, U Lassen, JM Sepulveda, M Khasraw, E Vauleon, Y Muragaki, AM Di Giacomo, N Butowski, P Roth, X Qian, AZ Fu, Y Liu, V Potter, AG Chalamandaris, K Tatsuoka, M Lim, M Weller
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.